About Avecho
Avecho is a company based in Notting Hill (Australia) founded in 1992. Avecho offers products and services including TPM Technology and CBD Soft-Gel Capsule. Avecho operates in a competitive market with competitors including Zoetis, Ceva, Ensysce, Arecor and Oxular, among others.
- Headquarter Notting Hill, Australia
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Avecho Biotechnology Limited
-
Annual Revenue
$699.95 K (USD)139.19as on Dec 31, 2024
-
Net Profit
-$1.93 M (USD)9.15as on Dec 31, 2024
-
EBITDA
-$2.98 M (USD)-9.14as on Dec 31, 2024
-
Latest Funding Round
$18.12 M (USD), Post-IPO
Jul 11, 2014
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Avecho
Avecho is a publicly listed company on the ASX with ticker symbol AVE in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Avecho
Avecho offers a comprehensive portfolio of products and services, including TPM Technology and CBD Soft-Gel Capsule.
Enhances delivery and effectiveness of medicines for various applications.
Treats insomnia through TPM-enhanced formulation in clinical trials.
Funding Insights of Avecho
Investments & Acquisitions by Avecho
Investment portfolio details for Avecho
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Avecho
Detailed financials for Avecho
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Avecho Comparisons
Peer comparison for Avecho
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Avecho
Avecho operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zoetis, Ceva, Ensysce, Arecor and Oxular, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Animal medicines, vaccines, and diagnostics are manufactured and supplied.
|
|
| Locked | Locked | Locked |
Animal health therapeutics are developed and supplied globally by Ceva.
|
|
| Locked | Locked | Locked |
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
|
| Locked | Locked | Locked |
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery
|
|
| Locked | Locked | Locked |
Drug delivery platforms and therapeutics for ophthalmology are developed.
|
|
| Locked | Locked | Locked |
Erythrocyte encapsulation systems for drug delivery are developed.
|
Detailed competitors of Avecho
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Avecho
Complete news archive for Avecho
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avecho
Avecho was founded in 1992 and raised its 1st funding round 22 years after it was founded.
Avecho is headquartered in Notting Hill, Australia. It is registered at Notting Hill, Victoria, Australia.
Paul Gavin is the current CEO of Avecho.
Annual revenue of Avecho is $699.95K as on Dec 31, 2024.
Avecho was founded in 1992 in Notting Hill, Australia, within the biotechnology sector focused on pharmaceutical delivery. A proprietary system known as Tocopheryl Phosphate Mixture (TPM), derived from vitamin E, is utilized to improve drug solubility and absorption through oral, dermal, and transdermal methods. Formulations incorporating TPM are being developed for low-solubility drugs targeted at human applications, with emphasis on safety for both human and animal health.
Avecho offers TPM Technology and CBD Soft-Gel Capsule.
Yes, Avecho is publicly traded on ASX under the ticker symbol AVE.
The ticker symbol of Avecho is AVE on ASX.